Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma — CA209-9KH

Locally Advanced Unresectable Pancreatic Adenocarcinoma Clinical Trial

Official title:
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

Status Completed

Clinical Trial Summary

Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

Clinical Trial Description

Phase I/II, multicentre, open label, with no control arm clinical trial of 4-weeks stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks in adults with locally advanced pancreatic cancer who does not progress during 4 cycles of standard chemotherapy FOLFIRINOX ;

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Locally Advanced Unresectable Pancreatic Adenocarcinoma

Clinical Trial Details

NCT number	NCT04098432
Study type	Interventional
Source	University Hospital Hradec Kralove
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	December 3, 2018
Completion date	September 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05919238` - Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma	Phase 1
Recruiting	`NCT04172532` - Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer	Phase 1/Phase 2
Recruiting	`NCT05078775` - Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer	N/A
Recruiting	`NCT04106856` - Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)	Phase 1
Active, not recruiting	`NCT03910387` - Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer	Phase 2